1. Home
  2. SVM vs KARD Comparison

SVM vs KARD Comparison

Compare SVM & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silvercorp Metals Inc.

SVM

Silvercorp Metals Inc.

HOLD

Current Price

$9.53

Market Cap

2.1B

ML Signal

HOLD

Logo Kardigan Inc. Common Stock

KARD

Kardigan Inc. Common Stock

N/A

Current Price

$19.83

Market Cap

1.8B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SVM
KARD
Founded
N/A
N/A
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.8B
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
SVM
KARD
Price
$9.53
$19.83
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$10.50
N/A
AVG Volume (30 Days)
2.2M
266.8K
Earning Date
05-25-2026
N/A
Dividend Yield
0.22%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$36.87
N/A
Revenue Next Year
$35.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.29
$19.58
52 Week High
$15.77
$27.00

Technical Indicators

Market Signals
Indicator
SVM
KARD
Relative Strength Index (RSI) 45.74 40.90
Support Level $8.68 $19.71
Resistance Level $10.19 $24.82
Average True Range (ATR) 0.44 1.69
MACD 0.09 -0.20
Stochastic Oscillator 56.21 6.18

Price Performance

Historical Comparison
SVM
KARD

About SVM Silvercorp Metals Inc.

Silvercorp Metals Inc is engaged in the acquisition, exploration, development, and mining of mineral properties. The Company's producing mines are located in China, and current exploration and development projects are located in China, Ecuador and Kyrgyz Republic. The company operates in single segment. The Company mainly produces and sells silver, lead, zinc, gold and other metals. The company's producing projects are Ying Mining District, GC Mine; construction projects are El Domo; permitting project is BYP Mine; development project includes Condor, Tulkubash/Kyzyltash.

About KARD Kardigan Inc. Common Stock

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

Share on Social Networks: